Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by MJP Associates Inc. ADV

MJP Associates Inc. ADV raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 15.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,797 shares of the medical research company’s stock after buying an additional 763 shares during the period. MJP Associates Inc. ADV’s holdings in Edwards Lifesciences were worth $547,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Advisors Asset Management Inc. boosted its stake in Edwards Lifesciences by 0.3% in the first quarter. Advisors Asset Management Inc. now owns 43,556 shares of the medical research company’s stock valued at $5,127,000 after acquiring an additional 117 shares during the last quarter. Apollon Wealth Management LLC grew its stake in Edwards Lifesciences by 1.0% in the 1st quarter. Apollon Wealth Management LLC now owns 12,487 shares of the medical research company’s stock worth $1,033,000 after buying an additional 119 shares in the last quarter. Geller Advisors LLC raised its position in Edwards Lifesciences by 6.5% during the first quarter. Geller Advisors LLC now owns 1,965 shares of the medical research company’s stock valued at $231,000 after purchasing an additional 120 shares in the last quarter. Allworth Financial LP raised its holdings in shares of Edwards Lifesciences by 2.5% during the 1st quarter. Allworth Financial LP now owns 5,015 shares of the medical research company’s stock valued at $415,000 after buying an additional 122 shares in the last quarter. Finally, Rockland Trust Co. raised its stake in shares of Edwards Lifesciences by 1.4% during the first quarter. Rockland Trust Co. now owns 8,639 shares of the medical research company’s stock worth $715,000 after acquiring an additional 122 shares in the last quarter. 79.25% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on EW shares. Mizuho lifted their target price on shares of Edwards Lifesciences from $95.00 to $102.00 in a research note on Monday, July 17th. Piper Sandler dropped their price objective on shares of Edwards Lifesciences from $88.00 to $83.00 and set a “neutral” rating on the stock in a research note on Friday, September 8th. Truist Financial raised their price target on Edwards Lifesciences from $101.00 to $105.00 in a report on Wednesday, July 19th. TheStreet cut Edwards Lifesciences from a “b-” rating to a “c+” rating in a research report on Wednesday, August 9th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $96.00 target price on shares of Edwards Lifesciences in a research report on Thursday, August 17th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus price target of $92.42.

Edwards Lifesciences Stock Down 0.3 %

EW stock traded down $0.25 during trading on Monday, hitting $72.95. 2,180,754 shares of the company’s stock were exchanged, compared to its average volume of 3,159,441. The business has a 50-day moving average price of $81.38 and a two-hundred day moving average price of $83.98. Edwards Lifesciences Co. has a 52-week low of $67.13 and a 52-week high of $94.87. The company has a current ratio of 3.15, a quick ratio of 2.30 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $44.35 billion, a price-to-earnings ratio of 32.01, a PEG ratio of 4.00 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.01. Edwards Lifesciences had a net margin of 24.56% and a return on equity of 25.43%. The firm had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.51 billion. During the same quarter last year, the firm earned $0.63 earnings per share. The firm’s revenue was up 11.4% compared to the same quarter last year. As a group, equities research analysts expect that Edwards Lifesciences Co. will post 2.55 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,660 shares of Edwards Lifesciences stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $73.63, for a total value of $637,635.80. Following the completion of the sale, the insider now owns 213,794 shares in the company, valued at approximately $15,741,652.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Edwards Lifesciences news, insider Larry L. Wood sold 8,660 shares of the stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $73.63, for a total value of $637,635.80. Following the completion of the sale, the insider now owns 213,794 shares of the company’s stock, valued at $15,741,652.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction dated Friday, June 30th. The stock was sold at an average price of $93.27, for a total value of $676,673.85. Following the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,795,260.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 174,359 shares of company stock valued at $14,301,522. 1.29% of the stock is owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.